$2.56
1.59%
Nasdaq, Fri, Aug 01 2025
ISIN
US68235C1071
Symbol
OCX

Oncocyte Corporation Stock price

$2.56
-0.48 15.79% 1M
+0.43 20.19% 6M
+0.18 7.56% YTD
-0.55 17.68% 1Y
-13.94 84.49% 3Y
-29.24 91.95% 5Y
-159.04 98.42% 10Y
-159.04 98.42% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.04 1.59%
ISIN
US68235C1071
Symbol
OCX

Key metrics

Basic
Market capitalization
$91.5m
Enterprise Value
$61.4m
Net debt
positive
Cash
$31.0m
Shares outstanding
28.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
23.8 | 29.8
EV/Sales
16.0 | 20.0
EV/FCF
negative
P/B
9.0
Financial Health
Equity Ratio
-35.0%
Return on Equity
496.4%
ROCE
-32.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.8m | $3.1m
EBITDA
$-15.4m | $-20.8m
EBIT
$-16.7m | $-25.1m
Net Income
$-58.3m | $-27.4m
Free Cash Flow
$-23.5m
Growth (TTM | estimate)
Revenue
178.3% | 63.6%
EBITDA
57.9% | -18.4%
EBIT
55.8% | -32.3%
Net Income
-42.6% | 55.0%
Free Cash Flow
-32.3%
Margin (TTM | estimate)
Gross
52.6%
EBITDA
-400.8% | -676.6%
EBIT
-433.9%
Net
-1,516.1% | -892.4%
Free Cash Flow
-612.5%
More
EPS
$-2.3
FCF per Share
$-0.8
Short interest
2.0%
Employees
48
Rev per Employee
$40.0k
Show more

Is Oncocyte Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Financial data from Oncocyte Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.84 3.84
178% 178%
100%
- Direct Costs 1.82 1.82
69% 69%
47%
2.02 2.02
552% 552%
53%
- Selling and Administrative Expenses 15 15
14% 14%
385%
- Research and Development Expense 9.36 9.36
16% 16%
244%
-15 -15
58% 58%
-401%
- Depreciation and Amortization 1.27 1.27
11% 11%
33%
EBIT (Operating Income) EBIT -17 -17
56% 56%
-434%
Net Profit -58 -58
43% 43%
-1,517%

In millions USD.

Don't miss a Thing! We will send you all news about Oncocyte Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncocyte Corporation Stock News

Neutral
GlobeNewsWire
about 2 months ago
New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” ...
Neutral
GlobeNewsWire
3 months ago
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion t...
Neutral
Seeking Alpha
3 months ago
OncoCyte Corporation (NASDAQ:OCX ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President & Chief Executive Officer Andrea James - Chief Financial Officer Ekke Schutz - Chief Science Officer Conference Call Participants Mark Massaro - BTIG Mason Carrico - Stephens Thomas Flaten - Lake Street Mike Mat...
More Oncocyte Corporation News

Company Profile

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Head office United States
CEO Joshua Riggs
Employees 48
Founded 2009
Website oncocyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today